Home
Zydus Lifesciences Limited
Press Release Jan 18 2025
Business
Jan 18 2025
3 min read

Press Release Jan 18 2025

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 18, 2025, titled "Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)".

View Attachment

Originaltext
Diese Übersetzung bewerten
Mit deinem Feedback können wir Google Übersetzer weiter verbessern